Our Shield™ blood test gains FDA approval, ushering in a new era of colorectal cancer screening.  More details

Guardant Access

is committed to making Shield™
accessible to all eligible patients

For Patients

  • Designed to limit surprise bills by notifying patients with an estimated out-of-pocket cost >$50
  • Eligible patients can receive financial assistance*

For Practices

  • We provide Shield-related eligibility confirmation, manage claims and appeals, and field all your patients’ billing questions

Any patient can enroll for financial assistance eligibility
determination on GuardantGO.com

Need help?

Phone: 1.855.722.7335, ext. 1, then press 2

Email: ScreeningSupport@guardanthealth.com

Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.

*In the event the test is not fully covered by insurance, patients may be eligible for financial assistance based on medical and financial need. To learn more, contact Guardant Health Client Services. For patients without insurance, the cash pay rate for Shield is $895 effective the first day of commercial launch, May 2, 2022.
Shield™ is a qualitative laboratory developed test intended to detect colorectal cancer by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
  • The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
  • Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
  • A "normal signal detected" Shield test result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
  • Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
Reference 1. Steele AM, DeBrow M. Efficiency gains with computerized provider order entry. In: Henriksen K, Battles JB, Keyes MA, Grady ML, eds. Advances in Patient Safety: New Directions and Alternative Approaches. 4th vol. US Agency for Healthcare Research and Quality; 2008. Accessed February 7, 2022. https://www.ncbi.nlm.nih.gov/books/NBK43766